Bluejay Therapeutics Reports First Preclinical Data for Liver-Targeted Fatty Acid Synthase (FASN) Inhibitor BJT-188 Being Investigated for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) 5/7/2025
FLEX Vessel Prep™ System FLEX FIRST AV Registry 6-Month Data and the Hamburg Vessel Prep Experience Prior to Angioplasty presented at Charing Cross Symposium - 4/23/2025
Glycosylation is crucial to the development of healthy organs and tissues. Could replacing a missing sugar help patients with a rare glycosylation disorder improve coordination and mobility?
Diabetes Treatment: A Story of Complicated Progress and Great Potential
RiverVest Managing Director Derek Rapp discusses the global health threat of diabetes and shares his thoughts on the innovation ecosystem that is essential to achieving better outcomes for patients.
RiverVest strives to improve the lives of patients, support entrepreneurs, and earn the trust of investors through science, strategy, and innovation.Contact us at info@rivervest.com
Transparency in Coverage Rule: To access the machine-readable files created and published by United Healthcare, please click here.